Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Epithelial Ovarian Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Urothelial Carcinoma|Non-Small Cell Lung Cancer|Small-Cell Lung Cancer|Endometrial Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer
Interventions: DRUG: SKB264
Sponsor: Klus Pharma Inc.